Craig Taylor Email & Phone Number

BS, Basel-City, CH

Nouscom is a clinical-stage immuno-oncology company developing next generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode large payloads of neoantigens, or other immunomodulators, and has clinically demonstrated the ability to safely and potently harness the power of the.

London, GB

Tenpoint is a biotechnology company pursuing vision-restoring, cell-based therapeutics and in vivo reprogramming to address degenerative ocular diseases. To date, we have raised $70 million in VC funding.

Tokyo, JP

Upon the successful acquisition of Adaptate Biotherapeutics by Takeda in April 2022, I carried on in my previous role and joined the Takeda team.

London, GB

Adaptate Biotherapeutics is an immunotherapy company developing therapeutic antibodies to modulate the activity of gamma delta T cells. Our exquisitely targeted approach enables us to harness and amplify the potential of patients’ own immune cells in situ, effectively addressing the challenges encountered by other immunotherapeutic approaches in treating.

London-based biotech that is transforming the prophylaxis and treatment of respiratory viral infections by developing a first-in-class, pan-viral RNA-based therapy

Cambridge, Cambridgeshire, GB

Congenica is a UK company founded on pioneering research from the Wellcome Trust Sanger Institute, NHS clinicians and regional genetic testing laboratories. We’ve translated this research into the gold standard clinical genomic analytics platform, Sapientia®, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians.

Nuremberg, Bavaria, DE

• Delivered strategic initiatives for pharmaceutical, biotechnology, and diagnostic clients in the areas of market strategy, opportunity analysis, pricing & reimbursement, health economics and market access.
• Analysed vast amounts of data from primary and secondary research programs, uncovering the key takeaways and delivering insightful, evidence-based recommendations to clients.
• Executed comprehensive interview programmes and advisory boards with high level KOLs, physicians and policy makers, distilling the key insights into actionable drug development strategies at the national and regional.

• Company 1:
• Provided a comprehensive opportunity analysis of non-invasive prenatal tests (NIPTs) to a newly formed genomic analysis companyCompany 2:
• Investigated both the research and clinical applications for a novel cell separation technology, providing strategic direction with the intent of spinning out a company (Birmingham, UK).
• Contributed as the commercial leader by evaluating the market size, competition, customers, patent strength, and regulatory landscape, as well as exploring potential funding opportunities.

Cambridge, Cambridgeshire, GB

• Identified potential pharma partners, evaluating their past acquisition/in-licensing targets, current M&A appetite, and drug pipeline, ultimately arriving at two target companies to pursue
• Assessed the attractiveness of Korean biotech market, identifying new business opportunities
• Investigated the firm’s IP position in relation to in-licensing technology from an external entity
• Delivered a robust competitor analysis, allowing for a more potent market positioning strategy

Seattle, WA, US

• Led negotiations of multi-year, international business agreements with key partners from Japan, Norway, Germany and The Netherlands, totaling US$13m in projected purchases (equal to 72% of revenue at the time)
• Provided operational guidance on cross functional product development teams (with responsibilities for concept evaluation through to product launch) that delivered 5 new initiatives to the market, including a breast.
• Through strategic procurement initiatives, generated a 9.5% margin increase on the company’s highest selling product, equating to 330% of an individual goal and 95% of the corporate goal that year
• Implemented an ISO 13485 quality system throughout the supply chain, allowing the company to proceed with regulatory approval to sell clinical diagnostic products
• Managed an annual procurement budget of US$8m

Seattle, WA, US

• Established the supply chain groundwork, enabling the launch of the first commercial product
• Reduced the purchasing price of 15 high-volume items by an average of 24%
• Negotiated new contracts with global logistic providers and utilized novel temperature controlled shipping containers to reduce shipping costs by 47%, passing the savings directly to customers
• Helped implement an ERP system, allowing the business to run more efficiently

Seattle, WA, US

• Led an organisational change initiative that enabled the Operations division to optimise performance by focusing on business critical issues
• Entrusted to manage the largest product portfolio within the organisation- US$82 million across 25 distribution centers
• Selected as co-Project Manager of the ‘Holiday Team’, overseeing both internal and external stakeholders to ensure completion of critical tasks for the global holiday launch, which is the company’s most important.

Thousand Oaks, CA, US

• Developed a business continuity plan, enabling uninterrupted operations in a natural disaster
• Created an inventory database that allowed the logistics team to fulfill orders more precisely, eliminating 80% of non value-added time

Mba, Finance Concentration

Bachelor Of Science, Manufacturing And Supply Chain Management

Associate Of Arts, General Studies With Business Emphasis